Evidence map›Paper›PMID 40786295›Full record

ArticleCureus2025

Diagnosis and Treatment of Plasmablastic Lymphoma in an Immunocompetent Patient: A Report of a Rare Case.

Pyrus Bhellum, Rajat Goyal, Satyendra Khichar, Vikarn Vishwajeet, Harshita Yalla

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pyrus BhellumDepartment of General Medicine, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND.
Rajat GoyalDepartment of General Medicine, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND.
Satyendra KhicharDepartment of General Medicine, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND.
Vikarn VishwajeetDepartment of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND.
Harshita YallaDepartment of Diagnostic and Interventional Radiology, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of diffuse large B-cell lymphoma (DLBCL), often associated with immunodeficiency states such as HIV infection. However, PBL can also occur in HIV-negative individuals, where it exhibits diverse anatomical involvement and poorer prognosis. This case presents a 50-year-old HIV negative male patient with progressive lower limb weakness and numbness due to a thoracic paravertebral lesion extending from T1 to T6, causing compressive myelopathy. Imaging raised concerns for malignancy, and histopathology confirmed PBL with positivity on IHC for CD38, CD138, and Cyclin D1. Given its aggressive nature, early intervention was critical. The patient underwent surgical decompression via T2-T6 laminectomy followed by chemotherapy with the EPOCH regimen (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). After two cycles, significant symptomatic improvement was observed. HIV-negative PBL is associated with poor prognosis and high relapse rates, necessitating aggressive treatment and close monitoring. This case highlights the challenges in diagnosing and managing HIV-negative PBL, emphasizing the importance of multimodal treatment strategies, including surgical intervention, intensive chemotherapy, and follow-up.

Indexed as

epochimmunocompetent adultplasmablastic lymphoma (pbl)plasmablastic myelomaspine tuberculosis

Identifiers

PMID40786295
PMCPMC12335865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.